Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, Inc. (VERV)
Company Research
Source: GlobeNewswire
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on February 29, 2024, the company granted equity awards to three new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received an aggregate of 16,300 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of April 1, 2024, subject to each such employee’s continued service with the company on each such vesting date. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment f
Show less
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
VERV
Earnings
- 11/7/23 - Beat
VERV
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- VERV's page on the SEC website